1. Home
  2. FRPT vs ACAD Comparison

FRPT vs ACAD Comparison

Compare FRPT & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Freshpet Inc.

FRPT

Freshpet Inc.

HOLD

Current Price

$60.35

Market Cap

3.9B

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$21.87

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRPT
ACAD
Founded
2004
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
3.9B
IPO Year
2014
2000

Fundamental Metrics

Financial Performance
Metric
FRPT
ACAD
Price
$60.35
$21.87
Analyst Decision
Buy
Buy
Analyst Count
17
22
Target Price
$80.29
$30.45
AVG Volume (30 Days)
1.7M
1.7M
Earning Date
05-04-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
183.87
69.12
EPS
2.64
2.30
Revenue
$1,102,015,000.00
$726,437,000.00
Revenue This Year
$11.34
$18.90
Revenue Next Year
$9.21
$11.62
P/E Ratio
$22.20
$9.11
Revenue Growth
13.01
40.45
52 Week Low
$46.76
$14.08
52 Week High
$89.80
$28.35

Technical Indicators

Market Signals
Indicator
FRPT
ACAD
Relative Strength Index (RSI) 28.40 48.65
Support Level $48.93 $20.45
Resistance Level $66.07 $22.75
Average True Range (ATR) 4.41 0.76
MACD -2.48 0.09
Stochastic Oscillator 25.35 71.57

Price Performance

Historical Comparison
FRPT
ACAD

About FRPT Freshpet Inc.

Freshpet produces and sells premium fresh pet food through its company-owned refrigerators placed in grocery, mass and club, pet specialty, and natural stores. Freshpet primarily targets dogs (96% of 2024 sales), with cats and treats comprising the rest of its sales. Geographically, the company's home US market, where all its food is produced, accounts for about 98% of sales, with exports to Canada, the United Kingdom, and other European countries accounting for the remaining balance.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: